These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 30503072)

  • 21. Topography of lymph node metastases in prostate cancer patients undergoing radical prostatectomy and extended lymphadenectomy: results of a combined molecular and histopathologic mapping study.
    Heck MM; Retz M; Bandur M; Souchay M; Vitzthum E; Weirich G; Mollenhauer M; Schuster T; Autenrieth M; Kübler H; Maurer T; Thalgott M; Herkommer K; Gschwend JE; Nawroth R
    Eur Urol; 2014 Aug; 66(2):222-9. PubMed ID: 23465520
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Salvage radiotherapy in patients affected by oligorecurrent pelvic nodal prostate cancer.
    Ingrosso G; Mariucci C; Tenti MV; Bini V; Alì E; Saldi S; Palumbo I; Bellavita R; Aristei C
    Clin Transl Oncol; 2020 Dec; 22(12):2236-2243. PubMed ID: 32418156
    [TBL] [Abstract][Full Text] [Related]  

  • 23.
    Herlemann A; Wenter V; Kretschmer A; Thierfelder KM; Bartenstein P; Faber C; Gildehaus FJ; Stief CG; Gratzke C; Fendler WP
    Eur Urol; 2016 Oct; 70(4):553-557. PubMed ID: 26810345
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radiotherapy in nodal oligorecurrent prostate cancer.
    Pinkawa M; Aebersold DM; Böhmer D; Flentje M; Ghadjar P; Schmidt-Hegemann NS; Höcht S; Hölscher T; Müller AC; Niehoff P; Sedlmayer F; Wolf F; Zamboglou C; Zips D; Wiegel T
    Strahlenther Onkol; 2021 Jul; 197(7):575-580. PubMed ID: 33914101
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oncological outcome of patients treated with spot-specific salvage lymphnode dissection (sLND) for positron-emission tomography (PET)-positive prostate cancer (PCa) relapse.
    Hiester A; Nini A; Niegisch G; Arsov C; Hautzel H; Antke C; Schimmöller L; Albers P; Rabenalt R
    World J Urol; 2019 Oct; 37(10):2081-2090. PubMed ID: 30643974
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of positive lymph nodes following radical prostatectomy.
    Heidenreich A; Rieke M; Mahjoub S; Pfister D
    Arch Esp Urol; 2019 Mar; 72(2):182-191. PubMed ID: 30855020
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Salvage Lymph Node Dissection for Nodal Recurrent Prostate Cancer: A Systematic Review.
    Ploussard G; Gandaglia G; Borgmann H; de Visschere P; Heidegger I; Kretschmer A; Mathieu R; Surcel C; Tilki D; Tsaur I; Valerio M; van den Bergh R; Ost P; Briganti A;
    Eur Urol; 2019 Oct; 76(4):493-504. PubMed ID: 30391078
    [TBL] [Abstract][Full Text] [Related]  

  • 28. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mid-term Outcomes Following Salvage Lymph Node Dissection for Prostate Cancer Nodal Recurrence Status Post-radical Prostatectomy.
    Zattoni F; Nehra A; Murphy CR; Rangel L; Mynderse L; Lowe V; Kwon E; Karnes RJ
    Eur Urol Focus; 2016 Dec; 2(5):522-531. PubMed ID: 28723518
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Elective nodal radiotherapy with a gapless radiation field junction for oligorecurrent prostate cancer after previous radiotherapy.
    Li M; Fan Y; Trapp C; Schmidt-Hegemann NS; Ma J; Buchner A; Lu S; Xu B; Stief C; Wang X; Zhou C; Belka C; Rogowski P
    Clin Transl Radiat Oncol; 2023 Mar; 39():100571. PubMed ID: 36605290
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictors of Recurrence After Metastasis-directed Therapy in Oligorecurrent Prostate Cancer Following Radical Prostatectomy.
    Milenkovic U; Kuijk J; Roussel E; Devos G; Van den Broeck T; Van Eecke H; Vanderstichele A; Duvillier T; Verhamme L; Van Haute W; Goeman L; Berghen C; Joniau S; De Meerleer G
    Eur Urol Oncol; 2023 Dec; 6(6):582-589. PubMed ID: 36878753
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Utility of [11C]choline PET/CT in guiding lesion-targeted salvage therapies in patients with prostate cancer recurrence localized to a single lymph node at imaging: results from a pathologically validated series.
    Passoni NM; Suardi N; Abdollah F; Picchio M; Giovacchini G; Messa C; Freschi M; Montorsi F; Briganti A
    Urol Oncol; 2014 Jan; 32(1):38.e9-16. PubMed ID: 23769269
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mapping Prostate Cancer Lesions Before and After Unsuccessful Salvage Lymph Node Dissection Using Repeat PSMA PET.
    Farolfi A; Ilhan H; Gafita A; Calais J; Barbato F; Weber M; Afshar-Oromieh A; Spohn F; Wetter A; Rischpler C; Hadaschik B; Pianori D; Fanti S; Haberkorn U; Eiber M; Herrmann K; Fendler WP
    J Nucl Med; 2020 Jul; 61(7):1037-1042. PubMed ID: 31806773
    [TBL] [Abstract][Full Text] [Related]  

  • 34. OLIGOPELVIS GETUG P07, a Multicenter Phase II Trial of Combined High-dose Salvage Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Node Relapses in Prostate Cancer.
    Supiot S; Vaugier L; Pasquier D; Buthaud X; Magné N; Peiffert D; Sargos P; Crehange G; Pommier P; Loos G; Hasbini A; Latorzeff I; Silva M; Denis F; Lagrange JL; Morvan C; Campion L; Blanc-Lapierre A
    Eur Urol; 2021 Oct; 80(4):405-414. PubMed ID: 34247896
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Which Patients with Clinically Node-positive Prostate Cancer Should Be Considered for Radical Prostatectomy as Part of Multimodal Treatment? The Impact of Nodal Burden on Long-term Outcomes.
    Gandaglia G; Soligo M; Battaglia A; Muilwijk T; Robesti D; Mazzone E; Barletta F; Fossati N; Moschini M; Bandini M; Joniau S; Karnes RJ; Montorsi F; Briganti A
    Eur Urol; 2019 May; 75(5):817-825. PubMed ID: 30409676
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Salvage lymphadenectomy after primary therapy with curative intent for prostate cancer.
    Quhal F; Bryniarski P; Rivas JG; Gandaglia G; Shariat SF; Rajwa P
    Curr Opin Urol; 2023 Jul; 33(4):269-273. PubMed ID: 37166270
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence and prognosis of low-volume, oligorecurrent, hormone-sensitive prostate cancer amenable to lesion ablative therapy.
    De Bruycker A; Lambert B; Claeys T; Delrue L; Mbah C; De Meerleer G; Villeirs G; De Vos F; De Man K; Decaestecker K; Fonteyne V; Lumen N; Ameye F; Billiet I; Joniau S; Vanhaverbeke F; Duthoy W; Ost P
    BJU Int; 2017 Dec; 120(6):815-821. PubMed ID: 28646594
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Salvage lymph node dissection with adjuvant radiotherapy for nodal recurrence of prostate cancer.
    Jilg CA; Rischke HC; Reske SN; Henne K; Grosu AL; Weber W; Drendel V; Schwardt M; Jandausch A; Schultze-Seemann W
    J Urol; 2012 Dec; 188(6):2190-7. PubMed ID: 23083862
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pattern of Progression after Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Nodal Recurrences.
    Ost P; Jereczek-Fossa BA; Van As N; Zilli T; Tree A; Henderson D; Orecchia R; Casamassima F; Surgo A; Miralbell R; De Meerleer G
    Clin Oncol (R Coll Radiol); 2016 Sep; 28(9):e115-20. PubMed ID: 27133946
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PET/CT and MRI directed extended salvage radiotherapy in recurrent prostate cancer with lymph node metastases.
    Rischke HC; Eiberger AK; Volegova-Neher N; Henne K; Krauss T; Grosu AL; Jilg CA
    Adv Med Sci; 2016 Sep; 61(2):212-218. PubMed ID: 26895459
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.